Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1083380 | 0.89 | CYP3A4 (0.64) | CYP3A4ALDH1A1KMT2AALOX15SMN1; SMN2 | |
| SCHEMBL1067494 | 0.83 | CYP3A4 (0.51) | CYP3A4ALDH1A1KMT2AALOX15SMN1; SMN2 | |
| SCHEMBL1071994 | 0.81 | ALDH1A1 (0.52) | CYP3A4ALDH1A1KMT2AALOX15SMN1; SMN2 | |
| SCHEMBL1069268 | 0.81 | CYP3A4 (0.49) | CYP3A4ALDH1A1KMT2AALOX15SMN1; SMN2 | |
| SCHEMBL4268012 | 0.79 | ALDH1A1 (0.42) | CYP3A4ALDH1A1PTGS1SLC7A5TSHR | |
| SCHEMBL607242 | 0.79 | SLC7A5 (0.56) | CYP3A4ALDH1A1KDM4ESLC7A5HSD17B10 | |
| SCHEMBL598432 | 0.79 | SLC7A5 (0.56) | CYP3A4ALDH1A1KDM4ESLC7A5HSD17B10 | |
| SCHEMBL10348263 | 0.78 | SMN1; SMN2 (0.41) | CYP3A4ALDH1A1SMN1; SMN2PTGS1SLC7A5 | |
| SCHEMBL13696625 | 0.78 | CYP3A4 (0.57) | CYP3A4ALDH1A1KMT2AALOX15SMN1; SMN2 | |
| SCHEMBL2515423 | 0.78 | ALPI (0.56) | CYP3A4ALDH1A1PTGS1SLC7A5TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575385-B2 | Process of making optically pure melphalan | NAVINTA LLC (US) | 2013-11-05 | — | — | US | claimed |
| EP-2268827-B1 | PROCESS OF MAKING OPTICALLY PURE MELPHALAN | NAVINTA LLC (US) | 2013-10-09 | — | — | EP | claimed |
| EP-2268827-A1 | PROCESS OF MAKING OPTICALLY PURE MELPHALAN | Navinta, llc. (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009117164-A1 | PROCESS OF MAKING OPTICALLY PURE MELPHALAN | NAVINTA LLC (US) | 2009-09-24 | — | — | WO | claimed |
| US-20090240074-A1 | Process Of Making Optically Pure Melphalan | PROVIDENT BANK | 2009-09-24 | — | — | US | claimed |
| US-8575385-B2 | Process of making optically pure melphalan | NAVINTA LLC (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2268827-B1 | PROCESS OF MAKING OPTICALLY PURE MELPHALAN | NAVINTA LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2268827-A1 | PROCESS OF MAKING OPTICALLY PURE MELPHALAN | Navinta, llc. (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117164-A1 | PROCESS OF MAKING OPTICALLY PURE MELPHALAN | NAVINTA LLC (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090240074-A1 | Process Of Making Optically Pure Melphalan | PROVIDENT BANK | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240074-A1 | Process Of Making Optically Pure Melphalan | TYR, PAH, TET2 | CYP3A4 121/4885ALDH1A1 717/4885KMT2A 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.